Novartis (NVS) Stock Forecast & Price Target

Novartis
Bear Case

Investors should be bearish about investing in Novartis AG for these reasons:

• Novartis AG faces significant legal and reputational risk as Pomerantz LLP is currently investigating claims on behalf of investors, which could lead to costly litigation and further pressure on the stock price.
• The company recently suffered two major pipeline setbacks in September 2026, with the Phase III Lp(a)HORIZON study for pelacarsen and the Phase III HARBOR study for del-desiran both failing to meet their primary endpoints, weakening confidence in its late-stage growth outlook.
• Analyst sentiment has turned cautious, with the consensus rating standing at "Hold" and recent downgrades from firms like Deutsche Bank, reflecting a lack of strong bullish conviction among sell-side professionals.
• Novartis AG is trading at a P/E ratio of 21.26, which may be considered expensive relative to its recent earnings growth, particularly given the recent negative outlook on future earnings estimates from research firms.
• Institutional investors have shown mixed behavior, with some large holders like Dodge & Cox and Goldman Sachs significantly reducing their positions in the second quarter of 2026, indicating potential concerns about the company's near-term trajectory.